Psychosis is often discussed as if it were a niche crisis, but the numbers stretch from 14.1 million US adults with serious mental illness to only 1 in about 14 people with schizophrenia receiving minimally adequate treatment in low and middle income countries. Even after treatment begins, gaps keep showing up, like first episode cases where around 70% had no prior care and schizophrenia where medication non adherence hits 40% at some point. This post pulls together the most telling findings so you can see where the system holds and where it breaks.
Key Takeaways
- 0.22% of the global population has bipolar disorder with psychotic symptoms (2019)
- 7.4% of people with schizophrenia receive minimally adequate treatment in low- and middle-income countries, per a global estimate (2019)
- 40.0% of people with schizophrenia report medication non-adherence at some point (varies by setting; systematic review estimate)
- Approximately 70% of people experiencing a first episode of psychosis have not received treatment before the onset of psychosis (duration of untreated psychosis estimates; meta-analytic findings)
- In the United States, 14.1 million adults (5.7% of adults) had serious mental illness in 2021 (includes psychosis disorders)
- In the UK, 1 in 6 people have a common mental disorder at some point (mental health baseline including overlap with severe illness pathways)
- In the US, 9.5% of adults with serious mental illness reported unmet need for treatment in the past year (2019 NSDUH)
- A 10-week reduction in DUP is associated with improved functional outcomes (meta-analysis; quantitative relationship)
- In a 2021 meta-analysis, cognitive behavioral therapy for psychosis (CBTp) reduced positive psychotic symptoms with a small-to-moderate effect size (SMD about -0.30)
- In a landmark trial, clozapine reduced suicide risk compared with other antipsychotics by 26% (hazard ratio 0.74)
- The schizophrenia treatment market is projected to reach $33.8 billion by 2030 (global), growing from 2023 (CAGR estimate)
- The antipsychotics market size is projected to reach $40.0 billion globally by 2028 (forecast), including atypical and typical agents
- The long-acting injectable antipsychotics market is forecast to grow to about $10.5 billion by 2031 (global), from ~$4-5B mid-2020s (forecast)
- In a US claims study, inpatient hospitalization costs comprised about 60% of total annual costs for schizophrenia patients (utilization-driven cost share)
- Schizophrenia-related healthcare costs in the US were estimated at about $155.7 billion in 2013 (direct + indirect; major estimate used in later literature)
Most people with first episode psychosis go untreated for months, while early and sustained care improves outcomes.
Related reading
01 · Category
Epidemiology1 stats
01
0.22% of the global population has bipolar disorder with psychotic symptoms (2019)
Interpretation
Epidemiology Interpretation
In epidemiology terms, about 0.22% of the global population is living with bipolar disorder that includes psychotic symptoms as of 2019, highlighting a relatively uncommon but clearly measurable condition worldwide.
02 · Category
Treatment Gap5 stats
01
7.4% of people with schizophrenia receive minimally adequate treatment in low- and middle-income countries, per a global estimate (2019)
02
40.0% of people with schizophrenia report medication non-adherence at some point (varies by setting; systematic review estimate)
03
Approximately 70% of people experiencing a first episode of psychosis have not received treatment before the onset of psychosis (duration of untreated psychosis estimates; meta-analytic findings)
04
The duration of untreated psychosis (DUP) median is 74 weeks in a pooled global analysis (psychosis before first treatment)
05
In a meta-analysis, antipsychotic discontinuation within 1 year occurred in 50% of patients with schizophrenia across studies
Interpretation
Treatment Gap Interpretation
From a treatment gap perspective, only 7.4% of people with schizophrenia in low- and middle-income countries receive minimally adequate care and delays are common with about 70% having no prior treatment before first-episode psychosis, while even after diagnosis medication non-adherence affects 40% and antipsychotic discontinuation reaches 50% within a year.
03 · Category
Healthcare Utilization7 stats
01
In the United States, 14.1 million adults (5.7% of adults) had serious mental illness in 2021 (includes psychosis disorders)
02
In the UK, 1 in 6 people have a common mental disorder at some point (mental health baseline including overlap with severe illness pathways)
03
In the US, 9.5% of adults with serious mental illness reported unmet need for treatment in the past year (2019 NSDUH)
04
In the EU, specialized early intervention services for psychosis are available in many countries but coverage remains limited; only 1.8% of mental health budgets are estimated to go to early intervention (Europe estimate)
05
Schizophrenia accounts for 4.5% of all psychiatric hospitalizations in the United States (healthcare utilization share)
06
Psychiatric emergency departments see frequent psychosis-related presentations; 17% of psychiatric ED visits involve psychotic symptoms (systematic review estimate)
07
Community mental health teams were associated with a 27% reduction in hospitalization rates for people with psychosis-spectrum disorders in a UK evaluation (system-level outcome)
Interpretation
Healthcare Utilization Interpretation
Across healthcare utilization, psychosis and related conditions consume a disproportionate share of services, from schizophrenia making up 4.5% of psychiatric hospitalizations in the US to 17% of psychiatric emergency department visits involving psychotic symptoms, even though early intervention reaches only 1.8% of mental health budgets in Europe and community mental health teams still reduced hospitalization by 27% in the UK.
04 · Category
Clinical Outcomes13 stats
01
A 10-week reduction in DUP is associated with improved functional outcomes (meta-analysis; quantitative relationship)
02
In a 2021 meta-analysis, cognitive behavioral therapy for psychosis (CBTp) reduced positive psychotic symptoms with a small-to-moderate effect size (SMD about -0.30)
03
In a landmark trial, clozapine reduced suicide risk compared with other antipsychotics by 26% (hazard ratio 0.74)
04
Electroconvulsive therapy (ECT) yields response in major depression; for psychosis-related catatonia, systematic reviews report response rates around 60% (quantitative review estimate)
05
Assertive Community Treatment (ACT) reduces rehospitalization by about 20% compared with standard care in controlled studies (meta-analytic estimate)
06
Integrated dual diagnosis treatment is associated with a 28% improvement in psychiatric hospital outcomes among patients with co-occurring psychosis and substance use (meta-analysis estimate)
07
Family interventions for schizophrenia reduce relapse rates by about 20% compared with control in meta-analyses
08
Digital therapeutics using computerized cognitive training improved cognitive performance by about 0.32 standard deviations in schizophrenia (meta-analysis)
09
Supported employment programs increase competitive employment rates by 63% vs. standard vocational services in people with serious mental illness (includes schizophrenia/psychosis)
10
Hospital length of stay for acute psychosis decreased by 15% after implementation of crisis resolution and home treatment services in UK analyses (quantified evaluation)
11
Long-acting injectable (LAI) antipsychotics reduce relapse by about 30% compared with oral antipsychotics in meta-analyses
12
Clozapine initiation is associated with a 40% reduction in hospitalization rate vs. prior treatment in real-world cohort analyses (quantified)
13
Early intervention services are associated with a 21% reduction in hospital admissions within 2 years (meta-analysis estimate)
Interpretation
Clinical Outcomes Interpretation
Across clinical outcomes, timely and targeted care shows measurable gains, with early intervention cutting hospital admissions by 21% and integrated dual diagnosis treatment improving psychiatric hospital outcomes by 28% for people with psychosis plus substance use.
More related reading
05 · Category
Market Size5 stats
01
The schizophrenia treatment market is projected to reach $33.8 billion by 2030 (global), growing from 2023 (CAGR estimate)
02
The antipsychotics market size is projected to reach $40.0 billion globally by 2028 (forecast), including atypical and typical agents
03
The long-acting injectable antipsychotics market is forecast to grow to about $10.5 billion by 2031 (global), from ~$4-5B mid-2020s (forecast)
04
The global behavioral health services market is expected to reach $245 billion by 2030 (forecast)
05
The global telehealth market is projected to reach $559 billion by 2030 (context for telepsychiatry enabling psychosis care)
Interpretation
Market Size Interpretation
The market opportunity for psychosis-related care is set to expand rapidly, with the schizophrenia treatment market projected to reach $33.8 billion by 2030 and antipsychotics reaching $40.0 billion by 2028, while long acting injectable antipsychotics grow to about $10.5 billion by 2031 as services and telehealth scale.
06 · Category
Cost Analysis11 stats
01
In a US claims study, inpatient hospitalization costs comprised about 60% of total annual costs for schizophrenia patients (utilization-driven cost share)
02
Schizophrenia-related healthcare costs in the US were estimated at about $155.7 billion in 2013 (direct + indirect; major estimate used in later literature)
03
A UK estimate puts annual societal costs of schizophrenia at about £11.0 billion (2010s estimate)
04
In the EU5 (France, Germany, Italy, Spain, UK), the economic burden of schizophrenia was estimated at €52.1 billion in 2015 (direct + indirect)
05
In a systematic review, indirect costs (productivity losses) account for the largest share of schizophrenia economic burden, often >50% of totals (review quantification)
06
In treatment-resistant schizophrenia, clozapine is associated with lower total costs than second-line alternatives in a US payer analysis (cost-difference quantified)
07
First-generation antipsychotics are generally lower cost than second-generation; real-world pharmacy cost differences between SGAs and FGAs range by agent but often exceed $1,000/year per patient in US claims (quantified in study)
08
A US claims study found LAI antipsychotics reduced total healthcare costs by about 10% vs. oral comparators among eligible populations (quantified)
09
Crisis stabilization services for psychosis have an average cost per episode of roughly $1,500–$2,500 (quantified range in US cost analysis)
10
In a schizophrenia payer burden model, medication-related costs account for about 20% of total direct costs, with hospital/ER comprising the rest (quantified model split)
11
Schizophrenia is associated with about 1.5–2.0 times higher overall healthcare utilization than matched controls in large datasets (quantified rate ratio)
Interpretation
Cost Analysis Interpretation
Across cost analyses, schizophrenia care costs in the US and Europe are dominated by utilization and indirect burden, with inpatient hospitalization driving roughly 60% of annual expenses in US claims studies and indirect productivity losses often exceeding 50% of the total economic burden.
07 · Category
Industry Trends7 stats
01
The US National Institutes of Health funded 1,200+ mental health research projects in 2020 (count of grants, includes psychosis-relevant research)
02
Between 2018 and 2022, telepsychiatry visit volume increased by 50x in the US (system-level metric)
03
In a global review, 65% of schizophrenia care programs include psychosocial interventions (percentage adoption across programs)
04
In Europe, around 1 in 3 countries report having a national early psychosis program or policy (international survey estimate)
05
Peer-support programs are implemented in at least 40% of community mental health settings in the UK (implementation estimate in survey)
06
Cognitive remediation is offered in about 30% of early psychosis services in certain European service mappings (service availability estimate)
07
In a US employer-sponsored mental health survey, 45% of workers reported needing support for mental health but 20% said access was limited (workforce access metric relevant to psychosis support pathways)
Interpretation
Industry Trends Interpretation
Industry Trends show that psychosis support is rapidly scaling and standardizing as NIH backed 1,200+ mental health research projects in 2020 and US telepsychiatry volume surged 50x from 2018 to 2022, while only 65% of schizophrenia care programs globally include psychosocial interventions, suggesting adoption is growing but still not universal.
08 · Category
User Adoption10 stats
01
The proportion of people with schizophrenia who are prescribed antipsychotics ranges from 60% to 80% in population studies (quantified range in systematic review)
02
In a cohort study, 55% of eligible patients received a long-acting injectable antipsychotic within 12 months of initiation (adoption metric)
03
In a US health-system study, 33% of patients with schizophrenia used patient portals for at least one mental health-related action (adoption proxy)
04
In a digital intervention trial, 68% of participants completed at least 75% of prescribed CBTp modules delivered digitally (engagement rate)
05
In app-based mental health studies, the median retention at 1 month is about 25% for psychosis-adjacent symptom tracking apps (quantitative synthesis)
06
In a schizophrenia telepsychiatry implementation study, 72% of scheduled follow-ups were completed via video visit vs. 58% via in-person within the same clinic network (uptake metric)
07
In a survey, 61% of clinicians reported using standardized rating scales (e.g., PANSS) routinely for psychosis treatment monitoring (adoption survey metric)
08
In a large cross-sectional survey, 29% of people with psychosis reported using peer support (uptake metric)
09
In a randomized trial, 80% of participants in a digital adherence intervention reported taking medication on ≥80% of days during follow-up (adherence adoption outcome)
10
Among people with early psychosis, 47% attended at least 4 early intervention sessions within 3 months (program uptake metric)
Interpretation
User Adoption Interpretation
Overall, user adoption looks uneven across psychosis care pathways, with uptake often moderate to high for core clinical interventions like antipsychotic prescribing (60% to 80%) and early sessions (47% within 3 months), but much lower for peer and digital engagement where only 29% use peer support and retention for symptom tracking apps drops to about 25% at one month.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Min-ji Park. (2026, February 13). Psychosis Statistics. Gitnux. https://gitnux.org/psychosis-statistics
MLA
Min-ji Park. "Psychosis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/psychosis-statistics.
Chicago
Min-ji Park. 2026. "Psychosis Statistics." Gitnux. https://gitnux.org/psychosis-statistics.
Sources & references
59 datasets cited across this report · attribution is report-level
+46 additional datasets cited (not shown individually)